# James Caruso

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/james-caruso
Canonical HTML page: https://getyourbrief.com/entity/james-caruso

## Timeline

- **2027-01-01**: Potential EU Launch — Target window for commercial availability of iopofosine I 131 in Europe.
- **2027-01-01**: Target Commercialization — Anticipated EU launch for iopofosine I 131 treatment of WM.
- **2026-09-30**: EMA Submission — Planned filing of Conditional Marketing Authorization for iopofosine I 131.
- **2026-09-30**: EMA Submission — Target window for filing the CMA for iopofosine I 131 in the European Union.
- **2026-06-30**: CLR 125 Data — Expected early data readout from Phase 1b study in triple-negative breast cancer.
- **2026-06-30**: CLR 125 Data Readout — Expected early data from the Phase 1b study in Triple Negative Breast Cancer.
- **2026-03-04**: Financial Results — Company reports 2025 results and provides corporate update.
- **2026-03-04**: Annual Results Announcement — CEO James Caruso provides corporate updates and confirms regulatory timelines.
- **2025-12-31**: Fiscal Year End — Cellectar completes a year of pipeline advancement and platform validation.
- **2025-12-31**: Fiscal Year End — Cellectar concludes a year focused on pipeline execution and supply chain strengthening.

## Recent coverage (2 stories, network-wide)

### Cellectar Biosciences Targets 2027 EU Launch for Iopofosine I 131
2026-03-05 01:14:41 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform.
Full story: https://getbiobrief.com/story/cellectar-biosciences-2025-results-iopofosine-update

### Cellectar Biosciences Targets 2027 EU Launch for Iopofosine I 131
2026-03-05 01:14:36 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

Cellectar Biosciences has announced its 2025 year-end results, highlighting a strategic shift toward European commercialization for its lead radiotherapeutic, iopofosine I 131. The company remains on track for a Q3 2026 regulatory submission to the EMA, while simultaneously advancing its Phase 1b study for CLR 125 in triple-negative breast cancer.
Full story: https://gethealthbrief.com/story/cellectar-biosciences-2025-results-iopofosine-update

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.